2 Growth Stocks to Buy For 2026 and Beyond

Company Overview - Vertex Pharmaceuticals' shares have increased by 13% year to date, which is slightly below the S&P 500, despite facing several setbacks and disappointing financial results [4] - The company has abandoned the development of certain pipeline candidates, including VX-264 for Type 1 diabetes [4] Future Prospects - Several factors could positively impact Vertex's financial results in the coming year, including meaningful pipeline progress and the potential launch of at least one new product [5] - Vertex launched Journavx, the first approved oral, non-opioid pain inhibitor, earlier this year, with expectations for significant progress in its top-line growth next year due to increased third-party coverage [6] - The company's Casgevy, approved two years ago for treating rare blood disorders, is also expected to make commercial strides in 2026 [6] Core Products - Vertex's core cystic fibrosis (CF) franchise remains robust, as its products are the only ones capable of addressing the underlying causes of the disease, with a significant number of patients still untreated [7] - The company has another medicine for Type 1 diabetes, zimislecel, which has shown promising results in clinical studies by reducing insulin dependence and severe hypoglycemic events [8] Market Expansion - DexCom is actively expanding its addressable market to address current challenges, indicating a strategic move to enhance its market position [8]